| Schedule of segment revenue and significant segment expenses |
| | | | | | | | | | | | | Rare Neurological Diseases Segment | | Three Months Ended June 30, | | Six Months Ended June 30, | | 2026 | | 2025 | | 2026 | | 2025 | Net product revenue | $ | 261,280 | | $ | 200,489 | | $ | 476,667 | | $ | 385,222 | Less: | | | | | | | | | | | | Cost of product sold (a) | | 63,191 | | | 38,147 | | | 107,696 | | | 70,134 | Research and development (b) | | 44,034 | | | 33,046 | | | 79,052 | | | 65,284 | Sales and marketing (c) | | 32,311 | | | 28,421 | | | 62,210 | | | 56,388 | General and administrative (d) | | 16,884 | | | 20,334 | | | 37,282 | | | 38,212 | Depreciation and amortization | | 5,968 | | | 5,967 | | | 11,936 | | | 11,935 | Stock-based compensation | | 9,576 | | | 11,394 | | | 19,884 | | | 23,844 | Interest expense | | 3,070 | | | 3,646 | | | 6,304 | | | 7,482 | Interest income | | (7,072) | | | (5,296) | | | (12,829) | | | (10,340) | Income tax expense | | 17,834 | | | 9,861 | | | 25,033 | | | 21,478 | Other segment items (e) | | 53 | | | 15,193 | | | 32,180 | | | 15,469 | Consolidated net income | $ | 75,431 | | $ | 39,776 | | $ | 107,919 | | $ | 85,336 |
| (a) | Cost of product sold excluding depreciation. |
| (b) | Research and development excluding stock-based compensation and IPR&D. |
| (c) | Sales and marketing excluding stock-based compensation. |
| (d) | General and administrative excluding stock-based compensation and amortization. |
| (e) | Other segment items include other expense, net and IPR&D charges. |
|